Tiziana Life Sciences (US) (TLSA) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tiziana Life Sciences announced promising results from their study of intranasal foralumab in treating non-active secondary progressive multiple sclerosis (na-SPMS), demonstrating a significant reduction in brain inflammation after three months. The breakthrough therapy, which modulates immune cells through a novel nasal delivery system, is paving the way for a new treatment avenue for neuroinflammatory conditions. These findings, supported by neuroimaging and clinical symptom assessments, are part of ongoing research to enhance the efficacy and safety of immunotherapies.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.